Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Pinellas Urology Inc

Neither a doctor nor a teaching hospital

Research payments

$175,041

38 payments

Through program year 2023, Pinellas Urology Inc is reported as receiving $175,041 in research payments, across 38 payments.

By program year

4 rows
Year Kind Amount Payments
2023 Research $1,741 1
2021 Research $18,358 9
2020 Research $39,936 14
2019 Research $115,006 14

Breakdown

Who paid Research payments · program years 2019–2023
  1. Boston Scientific Corporation $67,062 6 payments
  2. Allergan Inc. $56,184 13 payments
  3. Astellas Pharma Global Development $51,784 18 payments
  4. Urovant Sciences Inc $12 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. Rezum XL $67,062 6 payments
  2. A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence $48,988 11 payments
  3. A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) $18,178 5 payments
  4. A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) $16,713 7 payments
  5. A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC $15,152 5 payments
  6. A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Treatment, 2-Stage, Dose Finding Study Evaluating the Efficacy and Safety of Botox Intravesical Installation in Participants With Overactive Bladder and Urinary Incontinence. $5,562 1 payment
  7. A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) $1,741 1 payment
  8. A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence $1,633 1 payment
  9. A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) $12 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record